Renovorx announces pricing of $12.1 million underwritten public offering of common stock

Mountain view, calif.--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a life sciences company developing novel targeted oncology therapies and commercializing renovocath®, a novel, fda-cleared delivery platform, today announced the pricing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. all shares in the offering are being sold by renovorx. the gross proceeds from the offering.
RNXT Ratings Summary
RNXT Quant Ranking